What is Carlsmed, Inc. Common Stock's market cap?

Carlsmed, Inc. Common Stock (CARL) has a market capitalization of $305.6M and trades on NASDAQ.

What is Carlsmed, Inc. Common Stock's revenue and profitability?

Carlsmed, Inc. Common Stock generated $56.4M in trailing twelve-month revenue with a net loss of $32.6M, representing a net margin of -57.8%. Gross margin stands at 75.9%, with free cash flow of -$34.5M. These figures are based on the Q1 2026 filing.

Who are Carlsmed, Inc. Common Stock's competitors?

Carlsmed, Inc. Common Stock's key competitors include Orthofix Medical Inc., Globus Medical Inc., Alphatec Holdings, Inc., and others. These companies compete in similar markets and product categories.

Who does Carlsmed, Inc. Common Stock partner with?

Carlsmed, Inc. Common Stock's notable partners include BioMedGPS, Centers for Medicare and Medicaid Services.

Where is Carlsmed, Inc. Common Stock headquartered?

Carlsmed, Inc. Common Stock is headquartered in United States of America. It has been publicly traded since 2025.

Carlsmed, Inc. Common Stock

CARL

Carlsmed is a commercial-stage medical technology company that provides AI-enabled personalized surgical solutions for spine fusion.

Market cap

$305.56M-9.4%

Revenue$56.4M+74.9%

Net income-$32.6M-32.9%

Free cash flow-$34.5M—

EPS (diluted)-$3.66+40.1%

Trailing twelve months · change vs. prior year

Table of contents

Earnings

Q1 2026 report

May 5, 2026

Revenue$16.1MBeat by $1.2M EPS-$0.32Beat by $0.11

Read the full report

Next report

Jul 21, 2026 (In 3 weeks)

Revenue estimate$18.0M

EPS estimate-$0.43

Financials

Q1 2026

Income statement

See full

Revenue$16.1M+58.2%

Gross profit$12.4M+62.7%

Operating income-$9.3M-62.2%

Net income-$8.7M-51.8%

EPS (diluted)-$0.32+78.2%

Balance sheet

See full

Cash & equivalents$73.0M+68.1%

Total debt$17.3M—

Total equity$92.2M+220%

Total assets$118.8M—

Cash flow

See full

Operating cash flow-$13.0M-59.5%

CapEx$79.0K-4.8%

Free cash flow-$13.1M-58.8%

Valuation & ratios

Valuation

See full

Market cap$305.56M-9.4%

Enterprise value$249.8M—

P/S5.4×—

Profitability

See full

Gross margin75.9%+1.4pp

Operating margin-60.5%-10.2pp

Net margin-57.8%-11.2pp

FCF margin-61.1%—

Returns & leverage

See full

Debt / equity0.2×—

Current ratio11.9×—

Competitors

By market cap

Johnson & Johnson$589.48B

Stryker$121.18B

Medtronic$103.07B

Globus Medical$11.5B

Alphatec Holdings$1.4B

SI-BONE, Inc.$743.3M

Orthofix Medical Inc.$376.3M

Carlsmed, Inc. Common Stock$305.6M

By revenue growth

Carlsmed, Inc. Common Stock+74.9%

Globus Medical+23.5%

Alphatec Holdings+22.6%

SI-BONE, Inc.+16.8%

Stryker+8.8%

Medtronic+8.4%

Johnson & Johnson+7.9%

Orthofix Medical Inc.+2.6%

By net margin

Johnson & Johnson21.83%

Globus Medical18.92%

Stryker13.21%

Medtronic13.2%

Orthofix Medical Inc.-7.27%

SI-BONE, Inc.-8.1%

Alphatec Holdings-15.93%

Carlsmed, Inc. Common Stock-57.76%

Profile

Carlsmed is a commercial-stage medical technology company that provides AI-enabled personalized surgical solutions for spine fusion. The company utilizes proprietary algorithms to transform standard diagnostic imaging into patient-specific surgical plans and 3D-printed titanium interbody implants designed to improve spinal alignment and reduce revision surgery rates. Its core value proposition centers on shifting spine surgery from a one-size-fits-all approach with stock implants to a data-driven, personalized standard of care.

Competitive position

Carlsmed is a first-mover in providing commercially available patient-specific interbody technology platforms for lumbar and cervical fusions in the U.S., protected by a robust patent portfolio and a significant data moat of radiographic images.

GeographiesUnited States

Customer segmentsHealthcare Providers, Surgical Facilities

Business modelDirect-to-customer sales, Made-on-demand manufacturing, AI-as-a-Service

SuppliersContract Manufacturing Organizations (CMOs), 3D printing service providers, Medical-grade titanium suppliers, Diagnostic imaging data providers

CustomersHospitals, Ambulatory Surgical Centers, Medicare and Medicaid, Commercial health insurance payors

CountryUnited States of America

Listed2025

CEOMike Cordonnier

Websitecarlsmed.com

FilingsSEC EDGAR

Ask your AI about Carlsmed, Inc. Common Stock.

Connect your AI assistant and get a quick read on the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Carlsmed, Inc. Common Stock's market cap?: Carlsmed, Inc. Common Stock (CARL) has a market capitalization of $305.6M and trades on NASDAQ.
What is Carlsmed, Inc. Common Stock's revenue and profitability?: Carlsmed, Inc. Common Stock generated $56.4M in trailing twelve-month revenue with a net loss of $32.6M, representing a net margin of -57.8%. Gross margin stands at 75.9%, with free cash flow of -$34.5M. These figures are based on the Q1 2026 filing.
Who are Carlsmed, Inc. Common Stock's competitors?: Carlsmed, Inc. Common Stock's key competitors include Orthofix Medical Inc., Globus Medical Inc., Alphatec Holdings, Inc., and others. These companies compete in similar markets and product categories.
Who does Carlsmed, Inc. Common Stock partner with?: Carlsmed, Inc. Common Stock's notable partners include BioMedGPS, Centers for Medicare and Medicaid Services.
Where is Carlsmed, Inc. Common Stock headquartered?: Carlsmed, Inc. Common Stock is headquartered in United States of America. It has been publicly traded since 2025.